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Short Abstract  (<200 words) 
 
The genotype-phenotype relationship and the physiopathology of Down Syndrome (DS) have 
been explored in the last twenty years with more and more relevant mouse models. From the 
early age of transgenesis to the new CRISPR/CAS9-derived chromosomal engineering and 
the transchromosomic technologies, mouse models have been key to identify homologous 
genes or entire regions homologous to the human chromosome 21 that are necessary or 
sufficient to induce DS features, to investigate the complexity of the genetic interactions that 
are involved in DS and to explore therapeutic strategies. In this review we report the new 
developments made, how genomic data and new genetic tools have deeply changed our way 
of making models, extended our panel of animal models, and increased our understanding of 
the neurobiology of the disease. But even if we have made an incredible progress which 
promises to make DS a curable condition, we are facing new research challenges to nurture 
our knowledge of DS pathophysiology as a neurodevelopmental disorder with many 
comorbidities during ageing. 
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Introduction 
 
 
The Human chromosome 21 (Hsa21), the smallest autosomic chromosome of the human 
genome, was mapped and almost fully sequenced 19 years ago (Hattori et al., 2000, 
Chandler et al., 2007) and was the second chromosome published due to its small size and 
its major impact when found in 3 copies in Down syndrome (DS) or trisomy 21. The Hsa21 
contains the smallest percentage of all the human genes, a 1.42% (833 genes on the 
ENSEMBL assembly GRCh38.v95), and the gene density is around 17.8 genes per Mb, this is 
quite similar to the overall gene density of 19 genes per Mb. After chromosome 18, 
chromosome 21 has the highest percentage of long non-coding RNAs (lncRNAs) genes 
compared to protein coding genes (36.6% against 27.8%) and median percentage of short 
non-coding elements as miRNAs both in total and per Mb. The sequencing of several widely 
used lab animal models genomes as Mus musculus (mouse), Rattus norvegicus (rat), Danio 
rerio (zebrafish), Drosophila melanogaster (fruit fly) and C. elegans (worm), and the great 
Apes family, the gorilla (Gorilla gorilla), orangutan (Pongo pabelii) and chimpanzee (Pan 
troglodytes) made possible the use of comparative genomics to identify several genetic 
alterations and variants associated with specific human diseases. This major progress 
provided a precise view of the genetic organisation of the Hsa21. The sequence of the 
mouse genome in 2002 (Waterston et al., 2002) stimulated the development of DS mouse 
models over the last two decades (Dierssen et al., 2001a, Herault et al., 2017), increasing our 
understanding of DS conditions and test therapeutic avenues in preclinical models. In the 
context of DS, the characterisation of the conserved Hsa21 syntenic region in several animal 
models, such as those on mouse chromosomes 16, 17, 10 and 12 (Toyoda et al., 2002) (this 
analysis) and on rat chromosomes 20 and 11 (Herault et al., 2017), have served as the basis 
to develop several models. These carry different partial duplicated regions homologous to 
Hsa21. These mice are used to map which genes are susceptible to dosage imbalance and 
contribute to specific observed phenotypes. Thanks to the development of these animal 
models and their behavioural assessment, we have increased our understanding of DS 
phenotypes and identified targets for therapeutic interventions.  
 
I. Animal models for Down syndrome: lesson learnt from the Genomic 
organisation 
 
In this first part we will report a state-of-art compilation of all the genomic information 
available on Hsa21 and the homologues genes found in the most broadly used lab models 
and other animals where trisomy has occurred spontaneously. Then we will describe in 
depth all the different genomic elements present on the genome (coding and non-coding 
elements) in the context of all these species, with a focus on the most commonly used lab 
animal models of DS. Finally, we will detail the conservation of several highly relevant genes 
known to be associated with some of the phenotypes observed in people with DS and we 
will discuss the comorbidities. We will take taking advantage of The International Mouse 
Phenotyping Consortium (IMPC) to get knowledge about the function genes homologous to 
Hsa21, using their deep-phenotypying in mouse. Although their results is about KO, knowing 
the function of genes may help to understand their function in DS where they are 
overexpressed.  
We included the following lab animal species and used their genomic sequences: the worm 
C. elegans (Consortium, 1998); the fruit fly (Adams et al., 2000), rat (Gibbs et al., 2004), and 
zebrafish (Howe et al., 2013), and some non-human primates (chimpanzee (Consortium, 
2005), Orangutan (Locke et al., 2011)). The main reason to include non-human primate is 
that evolutionary speaking, humans are closer to these species. Moreover, two cases of 
trisomy were described in chimpanzee (McClure et al., 1969) and both orangutan and gorilla 
have conserved homologous genes to the Hsa21 in chromosome 22 (Luke et al., 1995), so, 
there natural trisomies may occur in these species that are analogues to DS, even though none 
has been described yet. 
Based on evolution, the Hsa21 region is more conserved between species that have a more 
recent common ancestor with Human, such as the Hominidae subclass species. The nuclear 
chromosome organization is a shared trait between all the Eukaryotic species. However, the 
rest of the genomic features are specie-specific although up to some degree these features can 
be conserved i.e. the number of chromosomes, their internal organization or the ratio of the 
different coding and non-coding elements present on each. To analyse in detail the genome 
features of these species, we queried the ENSEMBL (www.ensembl.org) database using 
biomaRt on the 270219 using the genomes assembly’s databases version 95.  
I.2 Human chromosome 21 genomic landscape 
I.2.1 Conservation of the Hsa21 genomic landscape 
The apparition of Hsa21 is dated long before the Cercopithecidae divergence (~ 55 million 
years ago). The ancestor of Hsa21 underwent several translocations with other chromosomes 
in Old World monkeys. Whereas in New World monkeys, it gained a bigger size on the 
species found (Richard and Dutrillaux, 1998). Thanks to the publication of several ZOO-FISH 
studies and whole genome sequencing projects, we can more easily and accurately rebuild the 
evolutionary history and map where the homologous genes of the Hsa21 on different species 
are located (Figure 1). Although it is important to consider that as the sequenced genomes are 
not fully completed both the mapping and evolutionary history inferred from these data may 
continue to develop.  
Interestingly, Hsa21 is the autosomal chromosome with the least number and percentage of 
genes. According to the most recent database, 833 genes are identified in total with 232 
protein coding genes, 380 non-coding RNA, 188 pseudogenes and 15 genes to be 
experimentally confirmed (TEC). Finally, this chromosome holds 8.762.696 variants 
described of all kinds. 
To address how conserved the orthologs are to the Hsa21 genes on the different species we 
extracted all the known ortholog genes that diverged by a speciation event, using ENSEMBL 
biomaRt R package (Brazma et al., 2005), and classified them in three categories:  
a) High confidence homologs: genes for whose ENSEMBL has a high confidence in the 
homology prediction annotation. 
b) Remote homologs when the confidence score in the homology was 0 and the sequence 
similarity was above 15% of the human gene with the other specie gene. 
c) Predicted genes: part from this category are genes with a high percentage of sequence 
similarity but where the confidence score was unknown. As the members of this 
category where mostly non-coding genes and predicted genes we decided to label this 
category as shown. 
Out of the 232 protein coding genes plus 380 non-coding genes found on Hsa21, the number 
of human genes where we find at least one ortholog in the Hominidae Subclade families of 
chimpanzee, gorilla and Orangutan are 261, 246 and 232 respectively. Two hundred and 
thirteen and 208 genes are conserved in rats and mouse genomes respectively. Finally, in 
zebrafish, fruit fly and worm 154, 98 and 83 homologs were found (Table 1). In all the cases 
most of the genes found were protein coding genes. Indeed, we are far from having a full 
description of all the non-coding genome of these species and to know about how 
evolutionary pressure acts on the non-coding genome. In addition, the overall percentage of 
non-coding elements is lower in the fruit fly genome compared to the mammal's species 
(19.62%). Thus, the number of homologous non-coding genes should be smaller than 
expected. Furthermore, the zebrafish genome is rich in repetitive sequences and the sequence 
is far from being resolved; two facts that may be strongly affecting the results about non 
coding genes. 
Approximately 75-million years separate humans and mice or rat in evolutionary 
time(Waterston et al., 2002). Nevertheless, the chromosomes have rearranged such as the 
Hsa21 homologous regions have split and the high confidence protein coding homologs 
genes are found in three orthologous regions on mouse chromosomes. When searching for 
Hsa21 homologs in the mouse and rat genome we were able to find one previously unknown 
high confidence mouse homolog located on Mmu12. Interestingly, most non-coding or 
predicted genes have homologs spread in a bigger number of either mouse or rat 
chromosomes than the protein coding genes that are highly conserved in chromosome units 
on mouse Mmu10, 16 and 17 (Mmu for Mus musculus chromosome; Figure 2) and on rats 
Rno11 and Rno20 (for Rattus Norvegicus chromosome). Additionally, the split Hsa21 regions 
in the mouse chromosomes are stable as no further inside rearrangements have occurred. 
Interestingly the non-coding genes inside Hsa21 that are classified as remote orthologs or 
predicted in mouse and rats, can be found spread in different chromosomes. Furthermore, at 
the start of Hsa21, on the short arm, between 5.07 and 7.8 Mb, there is another syntenic 
region where we can find a gene inversion in rat, gorilla, chimpanzee and orangutan. 
Interestingly there is a non-coding enriched region from 7.8 to 14.1 MBs containing one 
unique high confidence homolog protein coding gene, TPTE, followed by the IGHV1 cluster 
where all of the genes are found conserved in the animal species spread in several 
chromosomes and only the IGHV1 cluster is fully maintained as a syntenic block. 
Furthermore, there seems to be a high conservation in both the gene identity and the relative 
synteny of some Hsa21 genes across species. For example, DYRK1A that encodes a dual-
specificity tyrosine phosphorylation-regulated kinase has a highly conserved sequence (Figure 
3A) in several species and the organisation of its neighbouring genes observed in the Hsa21 is 
preserved across several mammalian species (Figure 3B). DYRK1A is a highly conserved gene 
in all the Hominidae subclade and rodent families both in sequence similarity and functional 
domains conservation. The homology relationship is one to one to one for most of the 
mammals and has a “one to many” homology relationships with zebrafish as it has two 
homologous genes called Dyrk1aa and Dyrk1ab. They have an 80.87 and 82.81 % of target 
sequence similarity and a 78.11 and 78.90 % of query sequence similarity respectively and 
Dyrk1aa has an assigned Gene Order Conservation score (GOCS) of 50, and a many to many 
homology relationships with the fruit fly and worm. In the case of fruit fly, the homolog with 
the higher sequence similarity is mnb with a 41.74 % of target similarity and a 57.27 % of 
query sequence similarity. The worm has several homologs mbk-1, Y111B2A.1, Y73B3A.16 
and C16A11.10. mbk-1 has the highest homology score with the human DYRK1A, 37.76 % of 
target sequence homology and 43.64 % of query sequence homology. 
I.4 Knowledge on the chromosomal organisation of the Hsa21  
The genome spatial organization inside the nucleus plays an important role in the control of 
gene expression and in consequence the genome function. Each chromosome can be divided 
into active and inactive compartments, and these further sub-divided in structural domains 
called Topologically Associated Domains, or TADs, that are an evolutionary conserved 
feature of the chromatin organization (Krefting et al., 2018). In the tri-dimensional frame, 
DNA segments physically interact with some other, more often than with others, these highly 
interacting sequences are likely to be part of the same TAD.  
TADs can be hundreds of kbs long, each isolated from the neighbouring TADs by boundary 
regions defined by the presence of certain boundaries elements such as CTCF binding sites, 
DNase I-hypersensitive sites, H3K36 trimethylation, transcription start sites and transcription 
factors like ZNF274 and SIX5 (Narendra et al., 2016, Hong and Kim, 2017). TADs can be 
further split in smaller domains referred as sub-TADs, although the definition of these 
domains and the understanding of their functionality is challenging (Phillips-Cremins et al., 
2013). TADs are known to coincide in size with replication timing domains (Wang et al., 
2017, Pope et al., 2014), and interestingly TADs are highly statically conserved between cell 
types and species when looking  at the Mb scale (Dixon et al., 2012, Li et al., 2018) although 
they are certainly dynamic at the kilobase scale and their genomic position can change 
depending on the cell type or developmental stage (Narendra et al., 2016). Some TADs 
known to be tissue-specific or development-stage specific. 
Spatial chromatin rearrangements disrupting the TADs structure due to genome duplications, 
deletions or inversions are the known cause of several diseases. For examples, the alteration 
of EPHA4-PAX3 TAD by disrupting a CTCF- associated boundary generate limb 
malformations (Lupiáñez et al., 2015); a deletion of 66kb upstream of LMNDB1 promoter 
deletes a TAD boundary and produces the interaction of three enhancers with the LMNDB1 
leading to overexpression of Lamin B1 and causing a rare neurological disorder characterized 
by a progressive central nervous system demyelination (Giorgio et al., 2015). In cancer TADs 
seem to be crucial, as 7307 mutations occurring in hESCs CTCF loops anchors were linked to 
several cancers as identified from the International Cancer Genome Consortium database 
(Zhang et al., 2011, Ji et al., 2016). Furthermore, some proto-oncogenes are insulated inside 
subTADs to control their activation (Hnisz et al., 2016). In Down syndrome patients (Zhang 
et al., 2018) and mouse models (Mowery et al., 2018) derived cell lines, the chromatin 
structure and accessibility are affected in several ways.  I.e.  a 22q11 deletion syndrome 
(22q11DS) DS patient derived lymphoblastoid cell line shows changes in chromatin marks, 
TADs domains, long-range interactions and gene expression suggesting that large genomic 
deletions modify nuclear organization and may derive into functional consequences (Zhang et 
al., 2018). In B-cells derived from Ts65Dn and Dp1Rhr mouse models, the Hsa21 encoded 
nucleosome binding protein HMGN1 was found critical to produce global chromatin 
regulatory alterations by increasing H3K27 acetylation and was linked to aberrant B-cell 
phenotypes found in people with DS. Interestingly, some people displayed partial duplications 
of Hsa21 and some DS models disrupt the TADs structure. Nevertheless, the consequence of 
these disruption remains unknown and opens an important field of study as the re-
arrangements in TADs and chromatin structure that may be contribute to the phenotypes. 
Comparing the diploid Hi-C build neuronal cortex TADs maps showing the human chr21q22 
region surrounding DYRK1A and the syntenic region in Mmu16, we can see a high 
conservation in the TADs structure, boundaries formation and gene content (Figure 4). Thus, 
it can be certainly useful to characterize the TADs landscape in DS brain cell in animal 
models to further understand the gene dysregulation and rise of phenotypes in patients 
carrying specific partial duplications due to the strong conservation of TADs saw in euploids 
individuals. 
II. Animal models to mimic dosage increase in DS 
Individuals with Down syndrome showed intellectual disabilities and several other abnormal 
features due to an additional copy of the Hsa21. Animal models already made it possible to 
get further knowledge on the pathophysiology of the condition. Most of the work have been 
done on mouse models but other species also contributed to the understanding of DS. 
Furthermore, rat models have been generated recently using CRISPR/Cas9 genome editing 
(Birling et al., 2017b) and they will certainly provide new opportunities to address more 
complex behavior. 
II.1 Non-Mammalian in vivo Model Systems 
II.1.1 Overexpression of genes in the Caenorhabditis elegans (nematode worm) 
C. elegans is a well-established genetic model and shows homology with 13.7 % of the genes 
from HSA21. To identify poorly characterized HSA21 genes required for nervous system 
function, Norquist and collaborators (Nordquist et al., 2018) performed a systematic 
functional characterization of HSA21 orthologs in C. elegans. They did a knockdown screen 
(RNA interference) and studied behavioural phenotypes caused by loss-of-function mutations 
in conserved HSA21 orthologs in the nematode. They found 10 HSA21 orthologs that are 
needed for neuromuscular behaviours: cle-1(COL18A1), cysl-2(CBS), dnsn-1(DONSON), 
eva-1(EVA1C), mtq-2(N6ATM1), ncam-1(NCAM2), pad-2(POFUT2), pdxk-1(PDXK), rnt-
1(RUNX1), and unc-26(SYNJ1). Of these ten genes, five are essential for development, based 
on the lethality phenotype seen in mouse knock-out models. They also found that three of 
these genes are needed for normal release of the neurotransmitter acetylcholine (the well-
known synaptic geneunc-26 (SYNJ1), as well as uncharacterized genes pdxk-1(PDXK) and 
mtq-2 (N6ATM1)). As the first systematic functional analysis of HSA21 orthologs, this study 
may serve as a platform to understand genes that underlie phenotypes associated with DS. 
II.1.2 Overexpression of genes in the Danio rerio (Zebrafish)  
Edie and collaborators (Edie et al., 2018) described the use of zebrafish to determine 
functions of HSA21 genes on early development. They chose cDNAs for 164 HSA21 genes, 
of which 149 have orthologs in zebrafish. These were transcribed in vitro and injected into 1–
2-cell zebrafish embryos and evaluated up to 5 days post-fertilization in order to perform the 
genetic dissection of dosage-sensitive gene effects on early development and understand the 
contribution of individual loci and their combinatorial effects to phenotypes relevant to the 
etiopathology of DS. Seven cDNAs, including those for superoxide dismutase (SOD1) and 2 
novel open reading frames, C21orf84 and C21orf57, resulted in cyclopia and/or U-shaped 
somites, phenotypes related to decreased sonic-hedgehog (Shh) signalling. The phenotype 
showed variable penetrance, which was increased with co-injection of 4 cDNAs with 
C21orf84 (Edie et al., 2018).  
Human and zebrafish DYRK1A protein sequence have 75.6% similarity and same function 
domains, suggesting an evolutionary conservation. A zebrafish model was used to detect the 
definite role of excessive expression of DYRK1A in primordial germ cells (PGCs) development 
during embryogenesis (Liu et al., 2017). DYRK1A mRNA was injected into embryos and the 
PGCs marker gene vasa and nanos1 were detected. Decreased number and disordered 
migration of PGCs were shown in zebrafish embryos overexpressing human or zebrafish 
DYRK1A (Liu et al., 2017). Quantitative proteome analysis showed that embryonic proteins 
were significantly altered in DYRK1A overexpressed embryos. Thus, overexpression of 
DYRK1A impairs PGCs development during early embryogenesis by altering key factors in 
embryos.  This work may provide a conceivable mechanism for the gonads and germ cells 
defects of Down syndrome patients. Nevertheless, it is difficult to compare the level of 
overexpression achieved by injection of mRNA with the presence of one more copy of 
DYRK1A in DS. 
II.2 Mammalian in vivo Model Systems  
II.2.2 The Ts65Dn and the accidental Ts1Cje models: DS mouse models V0 
At the end of the 1990s, two mouse models, Ts65Dn and Ts1Cje, were developed. These have 
allowed major advances in the understanding of DS. Both models were obtained by extensive 
screening of a genetic resource  (Reeves et al., 1995) or by chance  (Sago et al., 1998). These 
two lines are widely used by the DS community with more than 400 references for Ts65Dn 
and more than 50 references for Ts1Cje. Those segmental trisomic mouse models, which 
survive to adulthood and have three copies of multiple genes responsible for the DS 
phenotype have been used to explore aspects of neurodevelopment and neurodegeneration. 
These animal models show some but not all the pathological, biochemical, and transcriptional 
changes observed in DS. They also have the advantage of allowing for the testing of 
therapeutic agents to restore cognitive function (Herault et al., 2017).  
Nevertheless, those models are not perfect. Indeed, the Ts65Dn model has a translocation that 
results in an extra-small chromosome that holds the Mmu16 region App-Zbtb21 orthologous 
to Hsa21. These mice are trisomic for about two-thirds of the genes orthologous to Hsa21, but 
this additional chromosome also carries genes originating from the Mmu17 that are not 
related to DS disease, including about 46 protein-coding genes, 35 non-protein-coding genes 
and 35 pseudogenes. Although some Ts65Dn males are fertile (Moore et al., 2010), 
transmission is typically through the maternal germ line. Mothers are thus trisomic which 
generally not the case in humans. The Ts1Cje mice do not carry an extra chromosome but is 
trisomic for the genetic interval Sod1 to Mx1 orthologous to Hsa21. A translocation between 
the Mmu16 proximal to Sod1 and the very distal region of the Mmu12 occurred, with the 
Mmu16 breakpoint being between App and Sod1. A partial monosomy of Mmu12 
representing about 2 Mb is also present in Ts1Cje mice (Laffaire et al., 2009, Duchon et al., 
2011b). This deleted region contains 3 genes that are unrelated to DS but are related to either 
neuronal proliferation or maturation, embryogenesis or peripheral and central nervous system 
development.  
 
II.2.1 The early age of transgenic TG, YAC and BAC: DS mouse models V1.0 
The first technological advances in the generation of genetically modified mouse models was 
developed by Gordon & Ruddle (1981). They successfully introduced foreign DNA into the 
pronucleus of one-cell mouse embryo. Initially, mice generated consisted of simple fusion of 
few kilobases DNA constructs in plasmids, e.g. a specific promoter and a specific cDNA. 
Early stage of models based on additional transgenesis have been already reviewed (Dierssen 
et al., 2001b, Dierssen et al., 2009), thus, we concentrated on the insertion of Bacterial 
Artificial Chromosomes (BACs) or Yeast Artificial Chromosomes (YACs) sequences that can 
be used to integrate hundreds of kilobases. Unlike plasmid pronuclear injection, large 
genomic transgenes are more likely to produce copy number dependent transgene expression 
that is independent of positional effects and better recapitulate endogenous gene expression 
patterns (Chandler et al., 2007, Giraldo and Montoliu, 2001). YAC models have been 
developed and analysed to understand the contribution of some DS genes, including 
DYRK1A, to cognitive function and other features (Guedj et al., 2009, Sebrie et al., 2008, 
Rachidi et al., 2007, Roubertoux et al., 2006, Branchi et al., 2004, Chabert et al., 2004, Smith 
and Rubin, 1997, Smith et al., 1997, Smith et al., 1995). The use of BAC transgenesis to 
model DS is technically complex and time-consuming. More importantly, random integration 
can result in unexpected phenotypic effects by disruption of an endogenous gene (Smirnov et 
al., 2018). All these models are valuable tools, but they deserved a very detailed analysis to 
confirm their integrity. For example, it is important to control that no illegitimate 
recombination followed by cellular DNA repair activity took place during their random 
insertion into the genome (Yan et al., 2013): the transgene can be inserted at random as a 
concatemer into the genome. These concatemers are, most frequently, head-to-tail array 
(Brinster et al., 1981, Bishop and Smith, 1989), with nucleotide deletion or insertion at some 
ends (Rohan et al., 1990, Merrihew et al., 1996). Integration by concatemers means that the 
level of overexpression cannot be controlled, it needs to be evaluated in each transgenic line 
and may not be representative of the increase in expression in people with DS. Several 
transgenic mice with YAC and BAC containing Hsa21 genes have been developed over the 
years (Herault et al., 2017, Herault et al., 2012, Dierssen et al., 2009). Most of them 
concentrate on the Down syndrome critical region (Delabar et al., 1993) and a few on single 
genes such as the amyloid precursor protein (APP) (Lamb et al., 1993b), regulator of 
calcineurin 1 (Rcan1) (Xing et al., 2013), Synaptojanin 1 (Synj1) (Voronov et al., 2008) and 
Dyrk1a (Ahn et al., 2006, Guedj et al., 2012, Nguyen et al., 2018). YAC Transgenic mice 
containing additional copies of the amyloid precursor protein (APP) gene (Lamb et al., 
1993b), have been useful in producing the amyloid beta deposition characteristic of AD and 
DS, but not the Tau neurofibrillary tangles and cytoskeletal changes that are the hallmarks of 
these human disorders. Such models are useful in replicating aspects of pathogenesis and 
allow the testing of therapeutic agents to restore impaired function. For instance, BAC 
transgenic mice that contain only one copy of the complete human DYRK1A gene showed 
significant impairment in hippocampal-dependent memory tasks in a Morris water maze. 
Shifts in both long-term potentiation and long-term depression were observed, which suggest 
a role for DYRK1A in bidirectional synaptic plasticity. These mice represent a clinically 
relevant DYRK1A mouse model and provide a valuable tool for the in vivo study of 
mechanisms that underlie the learning and memory deficit in DS (Ahn et al., 2006).  
II.2.3 Chromosome engineering for DS mouse models V2.0 
During the 1990s, the development of chromosome engineering made possible to generate 
DS monosomic and trisomic lines with precisely selected intervals (Ramirez-Solis et al., 
1995, Herault et al., 1998). Chromosome engineering is based on the use if the cre site-
specific recombinase to generate megabase chromosome rearrangements. Basically, the cre 
enzyme recognize and catalyse site-specific recombination between two loxP attachment 
sites. When these two loxP sequences are on the same chromosome (i.e. in cis) and in the 
same orientation, the region between the loxP is deleted. If the loxP are in cis but in opposite 
direction, the region is inverted. Interestingly, if the loxP are on different chromosome (in 
trans), translocation events will occur. Duplication and deletion can be obtained in vitro in 
embryonic stem cells (Ramirez-Solis et al., 1995), or in vivo by targeted meiotic 
recombination (TAMERE) (Herault et al., 1998). Even if efficient, obtaining DS models 
though TAMERE can take several years as two mouse models containing loxP are to be 
generated and then crossed together with a line that expresses cre in male spermatocytes 
during the zygotene to early pachytene stages (i.e. when chromosome pairing occurs). 
Despite its complexity, cre/loxP chromosome engineering has resulted in many models of 
high value for deciphering DS mechanisms (Herault et al., 2012) both in mouse and now in rat 
(figure 5). 
II.2.4 Transchromosomic lines for DS mouse models V3.0 
Transchromosomic (i.e. trans-species aneuploidy) mouse strains are mice that carry an extra 
chromosome from another species and are thus trisomic only for the genes on this 
chromosome. Tc1 mouse model (formally called Tc(Hsa21)1TybEmcf) contains an additional 
Hsa21 (O'Doherty et al., 2005). The Hsa21 was transferred into mouse ES cells using 
irradiation microcell-mediated chromosome transfer. The Tc1 mouse line was then obtained 
using a classical ES cells injection approach: ES cells were injected into host blastocysts to 
generate chimeras, the later were then bred to obtained germline transmission. 
The Tc1 mice are functionally trisomic for ∼120 protein-coding genes (Ahmed et al., 2013) 
and most of the human Hsa21 genes are likely expressed at the mRNA, protein and functional 
levels (Reynolds et al., 2010). Combination of next generation sequencing, comparative 
genomic hybridization (CGH)-array and Fluorescence in situ Hybridization (FISH) 
technologies were used to analyse the structure of Tc1 Hsa21 chromosome (Gribble et al., 
2013). It revealed multiple structural rearrangements and mutations in genes of interest (such 
as APP), likely caused by gamma irradiation during the generation of the model. In addition, 
Tc1 mice are mosaic for the Hsa21 as this one is lost stochastically. Nevertheless, the Tc1 
mouse displays several cognitive, craniofacial and cardiac deficits that are related to DS 
(O'Doherty et al., 2005, Heise et al., 2015, Watson-Scales et al., 2018, Haas et al., 2013). 
Altogether the Tc1 model is very informative but we must keep in mind that in this model the 
human genes should be transcribed and spliced with the mouse machinery and that any 
interacting proteins coded by the human genes should interact with mouse proteins.  
II.2.5 Towards DS mouse models V2.2 with the advanced engineering by CRISPR/Cas9 & 
new resources 
In the last few years, CRISPR/Cas9 technological breakthrough and availability of large 
mutant lines resources are opening brand news possibilities to study DS. CRISPR-mediated 
rearrangement (CRISMERE) technology promises to replace chromosome engineering and 
mouse BAC overexpression in DS. The CRISMERE technology is very efficient and fast 
(Birling et al., 2017b). Two pairs of CRISPR guide RNA (sgRNA) are selected upstream or 
downstream of the region of interest and are injected with the Cas9 nuclease into one-cell 
mouse embryos. The Cas9 protein will generate double strand break at the vicinity of the 
region of interest and cells reparation mechanisms will result in very frequent structural 
variation events. The outcomes of the chromosomic recombination are different when Cas9 
edits the genome in mitosis phase G1 or G2, with DSBs in cis or in trans (see review (Birling 
et al., 2017a)). Deletions, inversions and/or duplications can occur in the very same founder 
and different lines can be obtained from a unique founder. The only limit is the viability of the 
allele. For instance, a rat line with the deletion of the complete Rno11 region (>24 Mb) was 
not obtained even if the very same deletion was detected in a founder which had also the 
duplication. This was not surprising as the monosomy of HSA21 is not viable (and RN011 
carries most of the gene located on HSA21). The line with the duplication is viable. High 
frequency of animals that show deletion, duplication or inversion of the region of interest are 
indeed observed (Birling et al., 2017a). Because CRISMERE is based on Mammalian cell 
repair and on the ability to inject CRISPR and Cas9 cocktail in embryos, this technology can 
likely be used in a large array of species. Rats DS models were already obtained (Birling et 
al., 2017a) and will help to better understand DS. Indeed, these rat models exhibit more 
complex and reciprocal social behavior than mouse models as already observed on models for 
autism spectrum disorders (Hamilton et al., 2014).  
III. Lessons learnt from the mouse models 
III.1 From phenotype to genotype  
III.1.1 Genotype-phenotype correlation in human 
DS is a complex syndrome with more than 80 possible traits. People with DS  are 
recognizable from their short stature and typical facial features and always have intellectual 
disability (ID) although with a high range of variability (IQ score from mild (~50-70) to severe 
(~20-35)(Kazemi et al., 2016). In addition to the neurodevelopmental defect leading to ID, 
97.4% of DS people develop neurodegenerative Alzheimer disease (AD) pathology starting at 
the age of 40 (Wisniewski et al., 1985, Mann and Esiri, 1989, McCarron et al., 2014, 
McCarron et al., 2005, Ballard et al., 2016, Head et al., 2015, Wiseman et al., 2015, 
McCarron et al., 2017). Low muscle tone and delay in the acquisition of both gross and fine 
motor skills are also present in most of the individual with DS (80%). However, the other 
traits are only present in a fraction of the individuals with congenital heart defects (CHD) 
present in 40-50% of the cases, acute megakaryoblastic leukemia (AMLK) occurring nearly 
500 times more than that of the general population or Hirschprung disease being present in 
2.6 % of the infants with DS at a higher frequency than in the euploid population (Lange, 
2000, Asim et al., 2015, Friedmacher and Puri, 2013).  
Since 1959, more than 60 years ago, we know that DS results from an additional copy of 
chromosome 21. Nevertheless, the only strong association of Hsa21 specific genes or 
chromosomal regions to this syndrome are mainly due to studies of partial trisomy. About 
95% of DS cases results from the complete extra copy of Hsa21, whereas rare cases of partial 
trisomies resulting from robertsonian translocations (~3%) have provided invaluable 
opportunities to study phenotype/genotype correlation and search for the Hsa21 loci 
responsible for the disease (Aula et al., 1973, Antonarakis, 1998). In 1974, a first review of 14 
People with DS  with partial trisomies delimited a 17.4 Mb distal 21q22 segment as essential 
for the development of DS typical features, excluding 65% of the Hsa21 (Niebuhr, 1974). 
Development of new cytological techniques such as fluorescent in situ hybridization (FISH) 
enabled more specific mapping which resulted in the determination of a more specific 
region of about 0.6 Mb within the 21q22 segment around D21S55 (between the DNA marker 
D21S17 and the gene ETS2) which was referred as the Down syndrome critical (or candidate) 
region (DSCR) or Down syndrome minimum chromosomal region (DCR)(Delabar et al., 1993, 
Rahmani et al., 1989, McCormick et al., 1989). However, this hypothesis of a single DSCR was 
refuted by Korenberg and collaborators as they reported new cases of people with DS with 
only Hsa21 proximal duplications (Korenberg et al., 1994, Korenberg et al., 1992, Nelson and 
Gibbs, 2004). In 2009, two geneticists groups identified genes regions of the Hsa21 
associated with specific phenotypes by using high-resolution mapping analyses with Array 
Comparative Genome Hybridization (CGH), further refuting the idea of a single critical region 
that would be responsible of all of the DS principal features (Korbel et al., 2009, Lyle et al., 
2009). A 2.82 Mb region at 21q22.2-22.3 including the DSCAM gene but excluding the 
foreseen DSCR genes KCNJ6, RCAN1 and DYRK1A was defined as involved in DS congenital 
heart disease while a 13 Mb containing also DSCAM was associated with Hirschsprung's 
disease and another 8.35 Mb region including RUNX1, ERG and ETS was proposed to 
contribute to both increased risk of transient myeloproliferative disorder (TMD) and acute 
megakaryoblastic leukemia (AMKL)(Korbel et al., 2009). Finally, they suggested that several 
regions were involved with ID (Korbel et al., 2009).  
III.1.2 Dissecting DS using a compendium of mouse models 
With only a few cases of partial T21 reported in the literature (Roizen and Patterson, 2003, 
Lyle et al., 2009, Korbel et al., 2009), there has been a need of animal models to further 
decipher genotype-phenotype relationships. The possibility of making large and specific 
chromosomal rearrangements using genetic engineering together with close relatedness to 
human has made of the mouse an invaluable model to study DS. Development of a large 
panel of targeted segmental trisomy mouse models has played a prominent role in 
deciphering the genetic complexity of DS. The presence of DS-related phenotypes has 
supported the validity of those models.   
A major consequence of T21 is an alteration of embryonic development leading to 31-54% of 
miscarriage and around 5% of stillbirth (Morris et al., 1999, Loane et al., 2013, Groen et al., 
2017) with the most common congenital anomalies associated being cardiac anomalies 
(44%) (Stoll et al., 2015). Fetal and postnatal loss associated to congenital heart defects have 
also been observed in DS mouse models (Shinohara et al., 2001, O'Doherty et al., 2005, 
Dunlevy et al., 2010, Li et al., 2007, Raveau et al., 2012, Lana-Elola et al., 2016) Going back to 
two copies of the 7.7 Mb App-Runx1 region in Ts65Dn mice by crossing it with the Ms5Yah 
model was able to rescue impaired postnatal viability (Raveau et al., 2012), while the 
comparison of two trisomic models with CHD, Dp3Tyb (Lana-Elola et al., 2016)  and Dp4Yey 
(Liu et al., 2014), highlighted to a small overlapping region from Mir802 to Kcnj6  to be 
cricital. Comparing mouse and human data, the Mx2-Zbtb21 segment present in the Dp3Tyb 
model was proposed as a critical region as it includes the 1.7 Mb DS CHD critical region (from 
DSCAM to ZBTB21) proposed by Korbel and collaborators (Korbel et al., 2009). However, no 
increase in CHD cases compared to wild-type animals could be observed in the Dp6Tyb 
model bearing a duplication of the Igsf5-Zbtb21 overlapping fragment, suggesting that this 
region might be necessary but not enough to trigger CHD in mice. 
Motor dysfunction and hypotonia are two major concerns in DS. Ts65Dn mice show 
locomotor deficits and its analysis enabled to partly understand the origin of this phenotype. 
Impaired coordination observed in those mice could be attributed to cerebellar dysfunction.  
Moreover, the atrophy of this structure and decreased number of granule cells first reported 
in the cerebellum of the mice were later reported in people with DS (Baxter et al., 2000, 
Pinter et al., 2001). Deficit in granular cell proliferation could be attributed to decreased 
Sonic Hedgehog signaling (Roper et al., 2006) but could not be linked to any specific trisomic 
gene.  The groups of Victor Tybulewicz and Elizabeth Fisher in London used a panel of mouse 
models with partial trisomies to map the genetic loci responsible for locomotor dysfunction. 
They excluded homologous regions on Mmu17 and 10 as well as the proximal part of the 
homologous region on Mmu16 (from Lipi to Mis18a) and pinpointed two small consecutive 
and non-overlapping regions spanning 3.3 Mb from Mir802 to Zbtb21 whose duplication led 
to locomotor deficit of the mice in the rotarod test(Watson-Scales et al., 2018). They also 
found motor neuron degeneration in the Dp(16)1Yey model spanning the entire Mmu16 
homologous region but could not linked to this phenotype to a specific smaller region, 
suggesting that this phenotype arise from two or more genes scattered along the Mmu16 
region. Nevertheless, this observation in the mouse led to new investigation in people with 
DS who were found to have the same decrease in motor neurons (Watson-Scales et al., 
2018). Further investigations by our laboratory contributed to the analysis of the DS 
locomotor deficits identifying as new pathological mechanisms and adding to the complexity 
of the phenotype.  Rescue experiment analysis by crossing the Tc1 transchromosomic model 
with a monosomic model for the Mmu17 Abcg1-U2af1 region partially rescued the 
locomotor deficit observed in the Tc1 model revealing a role of this region in locomotor 
function although the trisomic mouse model for this region did not present locomotor 
deficit(Marechal et al., 2015). We observed a mild locomotor deficit in trisomic mice for the 
Mmu16 proximal Hspa13-App region that was associated with decreased muscle endurance 
and oxidative capacity due to decreased mitochondrial content, shedding light on hypotonia 
and pointing at the Nrip1 gene as candidate for this phenotype (Brault et al., 2015).  
Cognitive deficit is by far the most disabling phenotype of DS and is present in all DS people, 
although with a high variability of severity. People with DS have a specific cognitive profile 
when compared with other persons with ID syndromes (Siarey et al., 1997, Conners et al., 
2011). They have impaired higher executive functions (Rowe et al., 2006) with difficulties in 
acquiring new skills(Pennington et al., 2003, Haxby, 1989, Nadel, 2003), verbal short-term 
memory (M Purser and Jarrold, 2005), visuospatial working (Vicari et al., 2005) and explicit 
long-term memory while showing relatively preserved emotional processes and implicit 
learning(Vicari et al., 2000).  
Those cognitive phenotypes have been assessed in trisomic mouse models using different 
tests such as the Y-maze or T-maze for working memory (Hughes, 2004), the long-term novel 
object recognition (NOR) task for explicit long-term memory (Cohen and Stackman, 2015) or 
the Morris water maze (MWM) task for spatial learning and memory and memory flexibility 
(Morris, 1984, D'Hooge and De Deyn, 2001). The Ts65Dn model, trisomic for the Mrpl39- 
Zbtb21 portion of the Mmu16, or the Ts1Cje trisomic for the Scaf4- Zbtb21 region, both 
containing the DSCR syntenic region were found to have DS-relevant cognitive phenotypes, 
validating the mouse as a model to study cognitive deficits in DS (Reeves et al., 1995, 
Escorihuela et al., 1998, Sago et al., 2000, Sago et al., 1998, Fernandez and Garner, 2008, 
Fernandez and Garner, 2007, Fernandez et al., 2007, Belichenko et al., 2007, Faizi et al., 
2011, Rueda et al., 2010, Martinez-Cue et al., 2005, Netzer et al., 2010, Olmos-Serrano et al., 
2016b). Moreover, the Tc1 model as well as the full trisomic model containing duplications 
of the three mouse syntenic regions, or with only trisomic the segment on Mmu16, also 
recapitulated those phenotypes (Morice et al., 2008, Galante et al., 2009, Yu et al., 2010a, 
Goodliffe et al., 2016, Olmos-Serrano et al., 2016a). Those models not only reproduced DS 
cognitive deficits but proved to be invaluable to observe physiological and structural changes 
in DS. For example, functional explorations of the hippocampus in the Tc1, Dp(16)1Yey and 
Ts65Dn models all revealed reduced long-term potentiation (LTP) that could explain 
hippocampal-associated memory deficits observed in the NOR or MWM tests(Morice et al., 
2008, Yu et al., 2010c, Kleschevnikov et al., 2004, Siarey et al., 1997) and in people with 
DS(Pennington et al., 2003). This decreased LTP was further associated to reduced 
glutamatergic NMDA receptors activation due to an increase in inhibitory gamma-
aminobutyric (GABA) neurotransmitter (Kleschevnikov et al., 2004, Costa and Grybko, 2005, 
Kurt et al., 2000).  
Further analyses of mouse models carrying a duplication of either the Mmu16, Mmu10 or 
Mmu17 syntenic region pointed at the importance of the Mmu16 region for most of the DS 
cognitive deficits (Yu et al., 2010c, Zhang et al., 2014), whereas Dp(17)1Yey and Dp1Yah mice 
having triplicated regions of the Mmu17 had only some learning impairment (Yu et al., 
2010c, Marechal et al., 2019b, Lopes Pereira et al., 2009) and the Dp(10)1Yey showed no 
learning or memory deficit (Yu et al., 2010c). The Mmu10 syntenic region was further 
excluded as a DS-ID-relevant region by a subtractive approach crossing the Tc1 model with a 
mouse model monosomic for the Cstb-Prmt2 region on Mmu10 which showed no rescue of 
the cognitive deficits observed in the Tc1 model (Duchon et al., 2011a). In order to test the 
role of the DSCR region as the region necessary for DS cognitive deficits, trisomic (Dp1Rhr, 
previously named Ts1Rhr) and monosomic (Df1Rhr, previously named Ms1Rhr) mouse 
models for the Cbr1-Fam3b syntenic region on Mmu16 were generated (Olson et al., 2004). 
The authors assessed the Dp1Rhr as well as the compound Ts65Dn/Df1Rhr model in the 
MWM test and found that while the Dp1Rhr model was not by itself sufficient to reproduce 
the lack of performance of Ts65Dn mice, returning to two copies of the DSCR in the 
Ts65Dn/Df1Rhr model could rescue spatial memory, suggesting that the DSCR is necessary 
but not sufficient for this phenotype (Olson et al., 2007). Interestingly in-depth investigations 
in behavior and neurobiology unravelled the impact of the DSCR on neurophysiology and 
synaptic phenotypes found in DS (Belichenko et al., 2009). 
The subtractive strategy was further used to assess the contribution of the single genes 
Dyrk1a (García-Cerro et al., 2017) or smaller region of the DSCR (Jiang et al., 2015). The 
complexity of the genetic interaction at work in DS was further demonstrated with the 
findings of new epistatic interactions when crossing different trisomic models together. 
Zhang and collaborators found that the increased LTP observed in the hippocampus of 
Dp(17)1Yey mice could be lowered back to normal by mating those mice with Dp(10)1Yey 
mice (Zhang et al., 2014), suggesting the genes in each segment have opposing effects on 
synaptic plasticity. They further showed that, when adding trisomy of the Mmu17 region to 
the Dp(16)1Yey model, the rescue of the deficit observed in the Dp(16)1Yey model by 
crossing with Ms1Rhr mice was no longer observed, suggesting epistatic interactions 
between trisomic genes on Mmu17 and  trisomic Mmu16 genes (Zhang et al., 2014). Our 
laboratory went further in deciphering the genes behind such epistatic interaction with Cbs 
found on Mmu17 and Dyrk1a on Mmu16 for their impact on DS-related memory deficits 
(Marechal et al., 2019b).  
Although an invariant aspect of DS, craniofacial morphology is the most striking example of 
the complex genotype-phenotype relationship at play in DS. People with DS  typically exhibit 
overall reduction in skull size with brachcephaly, a round face with close-set eyes, and 
smaller mandible and maxilla (Guihard-Costa et al., 2006, Farkas et al., 1985). Although 
different, the murine skull shares the same developmental programs with humans and 
comparative dysmorphologies have been documented between both the Ts65Dn and 
Dp(16)1Yey mouse models and the skulls of DS children(Starbuck et al., 2014, Richtsmeier et 
al., 2002, Richtsmeier et al., 2000, Hill et al., 2007). Both models display overall reduction in 
size, brachycephaly, reduced mandibular and maxilla size, and reduced interorbital breath 
(Starbuck et al., 2014, Richtsmeier et al., 2002, Richtsmeier et al., 2000). However, 
comparing skull morphology of the Ts65Dn model with models encompassing different 
Ts65Dn sub-regions (Ts1Cje, Scaf4-Mx1; Dp1Rhr, Cbr1-Fam3b; Ts65Dn/Df1Rhr, Mrpl39-Cbr1) 
showed that Dp1Rhr mice had a very different pattern of dysmorphologies compared to the 
others, revealing complex interactions (Aldridge et al., 2007, Olson et al., 2004).  
 
III.2 Highlighting the role of candidate genes 
 
III.2.1 The DSCR genes 
In the search for candidate genes responsible for DS phenotypes, focus has first been made 
on genes within the DSCR. The most studied gene in this region is the dual-specificity 
tyrosine (Y)-phosphorylation regulated kinase 1a (DYRK1A). DYRK1A has been found to be 
implicated in many cellular processes throughout brain development, adult brain function 
and aging (Tejedor and Hämmerle, 2011, Park and Chung, 2013, Becker et al., 2014, Abbassi 
et al., 2015, Duchon and Herault, 2016, Arbones et al., 2019). Mouse models, 
haploinsufficient (Dyrk1a+/- mice) (Fotaki et al., 2002, Raveau et al., 2018) or overexpressing 
Dyrk1a (TgDyrk1a mice) (Altafaj et al., 2001, Ahn et al., 2006, Guedj et al., 2009), have 
helped to decipher the role of DYRK1A in those different processes. Tg(Dyrk1a) mice 
recapitulate cognitive phenotypes observed in DS, such as neurodevelopmental delay, 
locomotor defects, and deficits in visuospatial learning, memory and flexibility (Ahn et al., 
2006, Altafaj et al., 2001, Souchet et al., 2014). The change in DYRK1A dosage has shown a 
huge impact on brain neurogenesis (Guedj et al., 2012). Overexpression of DYRK1A results in 
inhibition of the proliferation and premature differentiation of neuronal cell progenitors 
(Yabut et al., 2010). DYRK1A impacts cell proliferation via the regulation of some cell cycle 
proteins like cyclinD1, p21Kip1 and p53 (Park et al., 2010, Najas et al., 2015, Soppa et al., 
2014), promoting cell cycle exit (Hämmerle et al., 2011). Dyrk1a+/- mice showed that DYRK1A 
is also implicated in adult neurogenesis by affecting on EGFR-mediated signaling (Ferron et 
al., 2010). Mouse models have also uncovered the role of DYRK1A in neuritogenesis, 
synaptogenesis and synaptic activity. Both DYRK1A gain- and loss-of-function models have 
alterations in dendritic arborization and in density and morphology of dendritic spines 
(Altafaj et al., 2001, Fotaki et al., 2002, Benavides-Piccione et al., 2005, Lepagnol-Bestel et 
al., 2009, Martinez de Lagran et al., 2012, Thomazeau et al., 2014, Dang et al., 2018). Defect 
in axon guidance has been reported linked to the modulatory effect of DYRK1A on FGF 
signaling via phosphorylation of Sprouty2 (Aranda et al., 2008). Impact of DYRK1A in 
neuronal activity was visualized by reduced spontaneous neuronal activity, increase in the 
amplitude of miniature excitatory postsynaptic currents (mEPSCs) in prefrontal cortex 
pyramidal neurons and by the characterization of modifications in the hippocampal long-
term potentiation (LTP) and long-term depression (LTD) in mouse models overexpressing 
Dyrk1a (Ahn et al., 2006, Martinez de Lagran et al., 2012, Thomazeau et al., 2014, Souchet et 
al., 2014). Those phenotypes have been linked to impact of DYRK1A on the cytoskeletal 
machinery via phosphorylation of proteins implicated in actin and microtubules assembly 
(Colón-Ramos, 2009, Dowjat et al., 2012, Liu et al., 2008, Martinez de Lagran et al., 2012, 
Park et al., 2012, Aranda et al., 2008, Kaczmarski et al., 2014, Liu et al., 2009, Ori-McKenney 
et al., 2016, Scales et al., 2009, Ryoo et al., 2008, Woods et al., 2001). Neuronal function was 
also found to be affected by DYRK1A through impact on expression or translation of key 
synaptic proteins such as neuroligin1, TrkBT1, Bdnf, AchE-S, and AchE-R (Toiber et al., 2010), 
on the activity of key transcription factors (NFAT and CREB) or proteins (Gsk3b, Ras, Raf and 
MEK1) implicated in synaptic plasticity (Arron et al., 2006, Yang et al., 2001, Song et al., 
2015, Kelly and Rahmani, 2005), and on its interaction with key proteins involved in either 
neurotransmitter release or post-synaptic receptor trafficking. DYRK1A overexpression in 
different mouse models was also found to perturb the excitatory/inhibitory balance toward 
inhibition and was proposed as a mechanism to explain LTP and memory deficits observed in 
those models (Ahn et al., 2006, Fernandez et al., 2007, Souchet et al., 2014, Souchet et al., 
2015, García-Cerro et al., 2014, Catuara-Solarz et al., 2016). Another DSCR gene, called 
DSCR1 for DS critical region 1 protein or coding for calcineurin 1 (RCAN1) and an inhibitor of 
calcineurin-mediated signaling pathways (Fuentes et al., 2000), is also a good candidate for 
DS neurologic deficits. Both mouse models deficient in or overexpressing RCAN1 show 
present hippocampal-dependent learning and memory deficits, and impaired LTP and 
TgRCAN1 presented reduced dendritic spine density on hippocampal pyramidal neurons 
(Hoeffer et al., 2007, Martin et al., 2012). Change in LTP induction was associated with 
decreased phosphorylation of the proteins CAMKII and ERK1/2 (Xing et al., 2013). RCAN1 
was also reported to impair neurotrophin trafficking leading to aberrant development of the 
sympathetic nervous system (Patel et al., 2015). Moreover, RCAN1 was implicated in the 
regulation of mitochondrial function which was also found to be altered in murine DS 
models (Parra et al., 2018). The DSCR gene KCNJ6 encoding the G protein-coupled inwardly 
rectifying K+ channel type 2 (GIRK2) has also been studied in the context of DS. GIRK2 plays 
an important role in cell excitability via control of the membrane resting potential (Lüscher 
et al., 1997, Luján et al., 2009). Transgenic mice carrying copies of human KCNJ6 were found 
to have altered cardiac regulation suggesting that this gene contributes to cardiac anomalies 
observed in DS (Lignon et al., 2008). A study with another mouse model trisomic for the 
mouse Kcnj6 showed that overexpression of this gene induces DS neurological anomalies as 
trisomic mice had hippocampal-dependent learning and memory deficits associated with 
hindered depotentiation and accentuated long-term synaptic depression (Cooper et al., 
2012). The role of Kcnj6 in DS cognitive deficit was further evidenced by the rescue of the 
cognitive deficits observed in the Ts65Dn model when crossed with Kcnj6+/- mice 
(Kleschevnikov et al., 2017).  Other candidate genes present within the DSCR are the PCP4 
gene coding for the Purkinje cell protein 4, a small calmodulin-binding protein whose 
overexpression in TgPCP4 mice induces premature neuronal differentiation (Mouton-Liger et 
al., 2011, Mouton-Liger et al., 2014) while its normalization in the brain of Dp1Rhr trisomic 
mice rescues the cilia dysfunction observed in this model (Raveau et al., 2017) and DSCAM 
(Down syndrome cell adhesion molecule), a cell adhesion molecule is responsible for the 
alteration of actin dynamics in a neuronal cell line of Dp16 mice (Pérez-Núñez et al., 2016). 
Recently, RNA-Seq and ChIP-Seq analysis of the Dp1Rhr model showed that overexpression 
of the HMGN1 nucleosome remodeling protein could recapitulate the gene expression 
modifications observed in this model and this protein was necessary for the B cell acute 
lymphoblastic leukemia observed in People with DS  (Mowery et al., 2018).    
III.2.2 More than the DSCR:  
While for some DSCR genes, detailed functional analyses have strongly suggested a 
contribution of these genes to the DS phenotypes. Studies of mouse models with duplication 
outside of the DSCR have clearly demonstrated the role of non-DSCR Hsa21 genes. The 
Col18a1 gene on Mmu10 encoding endostatin, an inhibitor of angiogenesis, was shown in 
both human and animal models to be at the origin of the resistance against certain solid 
malignancies observed in DS. RIP140 (Nrip1 in the mouse) upstream of the DSCR and coding 
for the nuclear receptor-interacting protein 1 was implicated in muscle metabolism and 
mitochondrial dysfunction observed in DS (Izzo et al., 2014, Brault et al., 2015). Behavioral 
analysis of mouse models trisomic for the Hsa21 homologous region on Mmu17 clearly 
indicated the presence in this region of one or more genes implicated in cognitive deficits 
(Lopes Pereira et al., 2009, Yu et al., 2010b). Further rescue experiment pointed at the gene 
CBS as being responsible for the cognitive phenotype observed in mice trisomic for this 
region (Marechal et al., 2019a). CBS codes for the Cystathionine-beta-synthase enzyme 
involved in homocysteine metabolism, with CBS loss-of-function leading to homocystinuria, 
a metabolic condition linked to intellectual disability (OMIM236200). CBS is also the major 
enzyme catalyzing the production of H2S in the brain, a gasotransmitter implicated in 
neuronal synaptic plasticity (Hu et al., 2011). CBS was found to genetically interact with 
DYRK1A although the underlying mechanism of this interaction still is unknown (Marechal et 
al. 2019). The APP gene present upstream of the DSCR on Mmu16 codes for an integral 
membrane protein whose proteolysis generates several derivatives as beta-amyloid (Aβ) 
polypeptide (Aβ40 and Aβ42) and whose amyloid fibrillary form is found in the brain of 
patients with Alzheimer’s disease (AD). Overexpression of this gene is responsible of the 
neurodegeneration and AD like neuropathological features observed in people with DS 
(Salehi et al., 2006). App triplication in the mouse Ts65Dn model did not result in Aβ deposit 
(Lamb et al., 1993a) suggesting that other factors are also required to get the full AD 
pathology. Still, APP overexpression in transgenic mouse models with the human gene or in 
the Ts65Dn model causes neuronal degeneration (Ghosal et al., 2009, Simón et al., 2009) 
which was associated with disruption of nerve growth factor (NGF) transport (Salehi et al., 
2006). Triplication of other Hsa21 genes have been subsequently found participating to the 
AD pathology in DS or AD models. Increasing S100B whose gene is present on the Mmu10 
syntenic region leads to exacerbated cerebral amyloidosis and reactive gliosis in the Tg2576 
APP transgenic mouse model (Mori et al., 2010). DYRK1A and RCAN1 overexpression result 
in tau hyperphosphorylation, suggesting that these two proteins participate in the formation 
of the neurofibrillary tangles that are the other hallmark of AD (Ryoo et al., 2008, Wegiel et 
al., 2011).  Moreover, DYRK1A overexpression has been proposed to phosphorylate APP, 
facilitating APP cleavage by BACE1 and the γ-secretase processing into Aβ40 and Aβ42 (Ryoo 
et al., 2008, Lee et al., 2003, Vingtdeux et al., 2005, Pathak et al., 2018, García-Cerro et al., 
2017). A cooperative interaction has been revealed between DYRK1A and RCAN1 on 
transcriptional activity via the suppression of the activity of the transcription factor NFAT 
and resulting in a delay of neuron production during corticogenesis (Kurabayashi and 
Sanada, 2013). Additionally, Song and collaborators showed that DYRK1A is able to 
phosphorylate RCAN1, leading to its aggregation (Song et al., 2013). The complexity of the 
gene interaction at work in DS was further highlighted by the identification of non-Hsa21 
isoforms contributing to the phenotypic variation with mutations in the GATA1 transcription 
factor found on the X chromosome leading to AMLK only in combination with trisomy of the 
Hsa21 (Crispino, 2005). Recently, some Hsa21 non-coding gene elements have been 
implicated in DS phenotypes. Five of the 29 miRNAs found of Hsa21 have been associated 
with DS pathogenesis (Chao et al., 2007, Keck-Wherley et al., 2011, Wang et al., 2013, Brás 
et al., 2018).  
III.2.3 Integration of new knowledge on the function of genes homologous to human 
chromosome 21 using mouse resource  
The “gene dosage effect” hypothesis proposing that DS phenotypes are caused by the 
cumulative effects of some of the triplicated genes stays the prevailing hypothesis in DS. 
Hence, knowledge of Hsa21 genes function and expression patterns is an essential step in 
finding the trisomic genes with potential relevance to the syndrome.  
Analysis of gene expression patterns in different tissues and at key stages of organism 
development enables to detect genes with specific temporal and spatial expression, linking 
those genes with specific ontogenic processes (Gitton et al., 2002). The mouse remains a 
resource of choice for gene expression analysis as blocks of orthologous genes expression 
was shown to be well conserved between mouse and human (Zheng-Bradley et al., 2010). 
Over the past twenty years, numerous publicly available mouse gene expression databases 
and digital gene expression atlases such as MAMEP (http://mamep.molgen.mpg.de), 
EMBRYS (Yokoyama et al., 2009) (http://www.embrys.jp), GenePaint (Carson et al., 2002) 
(http://www.genepaint.org), EURExpress (Diez-Roux et al., 2011) 
(http://www.eurexpress.org), EuRe-Gene (Raciti et al., 2008) 
(http://www.euregene.org/portal), BGEM (Magdaleno et al., 2006, Heintz, 2004) 
(http://www.gensat.org), the Allen Brain Atlas (Lein et al., 2007) (http://portal.brain-
map.org/), EMAGE (http://www.emouseatlas.org/emage) and based on in situ hybridization 
and high-throughput gene expression data have been developed and offer invaluable tools 
to visualize gene expression with spatiotemporal resolution. Some of these data are 
available in some integrated resources such as the Gene Expression Database (GXD, 
http://www.informatics.jax.org/expression.shtml) and the Gene Expression Omnibus (GEO, 
https://www.ncbi.nlm.nih.gov/geo/).  
With the recent development of single-cell RNA-Sequencing, resolution of gene expression 
now reaches single cells. This new technique has enabled to dig into cell population diversity 
and cell type identification revealing rare populations of cells and leading to transcriptome-
based single cell databases and atlases (DropViz: http://dropviz.org/, (Saunders et al., 2018, 
Tasic et al., 2016); Single cell expression atlas: https://www.ebi.ac.uk/gxa/sc/home; Adult 
mouse cortical cell taxonomy: http://casestudies.brain-map.org/celltax, (Tasic et al., 2016)). 
Using Microwell-Seq, Han and collaborators profiled over fifty mouse organs, tissues and cell 
lines providing a mouse cell atlas database that will also include proteomic data (such as 
CyTOF data) and spatial information (such as in situ data) to provide a more complete atlas 
with multi-omic information (Han et al., 2018). Moreover, new technological advances will 
allow in the future to obtain multiple omics information as well as serial time point measures 
from the same cell giving invaluable information to understand how over-expression of given 
trisomic genes can affect specific cells during specific time points either during development 
or in the adult (Dey et al., 2015, Macaulay et al., 2015, Harbom et al., 2016) 
(http://commonfund.nih.gov/singlecell/challenge). 
Protein functional analysis has benefit from the development in the 1980s of the Cre/loxP 
technology in mouse embryonic stem (ES) cells, enabling to produce mutant mice. At the 
beginning of the 2000s, the International Knockout Mouse consortium (IKMC) federated the 
Knockout Mouse Project (KOMP) in the US, together with the North American Conditional 
Mouse Mutagenesis Project (NorCOMM) in Canada and the European Conditional Mouse 
Mutagenesis Program (EUCOMM) to mutate all the protein-coding genes in the mouse using 
gene trapping and gene targeting in C57BL/6 mouse ES cells (Collins et al., 2007). Similarly, a 
collaborative effort was done to provide standardized protocols for the phenotypic 
characterization of the knockout mice (http://eumorphia.org; http://www.eumodic.org). 
Since 2012, the International Mouse Phenotyping Consortium (IMPC) has been coordinating 
all those efforts, generating and phenotyping 20,000 knockout mouse strains. This 
consortium produces the knock-outs of all the protein coding genes located in syntenic 
Hsa21 murine regions. All these lines will be available to study systematically, gene per gene 
to assess the importance of each of them in the DS phenotypes. Today, many knock-out for 
mouse orthologues to Hsa21 genes are already available and some were already phenotyped 
through the EMPReSS standard protocol (PMID: 28650483). Systematic knock-out strategies 
will give new insights about the function of the genes located in Hsa21 and may identify new 
DS candidate genes. Moreover, the ES clones also allows tissue- or cell-specific conditional 
gene knockout using spatially and temporally regulated Cre recombinases. Alternatively, the 
IMPC knock-out lines can also be bred to different trisomic or duplication models to confirm 
the role of a specific gene in DS phenotype. This approach should also make possible to 
establish a list of genes as potential targets for treating the disease.  
Of the 208 mouse orthologs to Hsa21 genes, only 52 have been selected on a first screen by 
the IMPC process to produce the complete Knock-out models and do the phenotypical 
analysis (Table 2). Looking at the different features, 14 classes of phenotypes were observed 
in embryo or adult state and the main systems altered are behaviour/neurological, mortality 
(embryo or pre-weaning lethality), homeostasis/metabolism, growth/size/body region. These 
phenotypes where observed in one or both sexes and in different zygosity states. Fourty-seven 
genes out of 52 showed more than one phenotype in controlling development, behaviour or 
metabolism; that are affected in DS. Thus, Hsa21 genes displayed a potential high degree of 
genetic interaction in diverse biological domains affected in DS, even though knockout 
phenotypes may not recapitulate the changes associated with DS, as these are linked to 
increased gene dose. 
 III.2.4 Finding altered pathways  
As the elevated expression of a Hsa21 gene in DS is a hint of its potential relevance to the 
pathology, accumulating data on transcriptional and proteomic analyses from human and 
mouse T21 has been invaluable to find gene dosage sensitive genes that might contribute to 
DS associated phenotypes. As well as the pathways that could be targeted therapies. Those 
analyses have revealed a large panel of molecular pathways and cellular processes that are 
perturbed in DS, however with sometimes contrasting results (Kahlem et al., 2004, Aït 
Yahya-Graison et al., 2007, Chou et al., 2008, Chrast et al., 2000). Meta-analysis of human 
and/or murine data revealed perturbation of some pathways involved in many cellular and 
molecular processes such as cell cycle, cytoskeleton organization, apoptosis, energy 
metabolism, cellular stress response, immune response, proteasomal activity, transcriptional 
activity, DNA repair or epigenetic mechanisms (Vilardell et al., 2011, Guedj et al., 2016, 
Pelleri et al., 2018).  
Granular cell precursors in the cerebellum as well as neural crest cells of Ts65Dn mice were 
found to have reduced response to the mitogenic factor Shh leading to cerebellar hypo-
cellularity, craniofacial dysmorphism and a hypoplastic dorsal mesenchymal protrusion that 
leads to an atrioventricular septal defect (Baxter et al., 2000, Currier et al., 2012). The mTOR 
pathway implicated in cell growth and survival was found to be deregulated in the 
hippocampus of Ts1Cje and Dp(10)1Yey mice, in the brain of Tc1 mice and in the frontal 
cortex from DS human autopsies (Troca-Marín et al., 2014, Block et al., 2015, Ahmed et al., 
2013, Perluigi et al., 2014) and has been associated with the AD pathology (Di Domenico et 
al., 2018).  
Guedj and collaborators (Guedj et al., 2015) found that NFAT signaling was perturbed in the 
brain of Ts1Cje mice. A mathematical model predicted that increased DSCR1 and DYRK1A 
trisomic gene dosage could synergistically act to reduce nuclear occupancy of NFAT proteins, 
leading to misregulation of genes critical to neural, skeletal and immune development 
(Arron et al., 2006).  
Energy metabolism was found to be perturbed in both human DS cell lines and mouse DS 
models, leading to increased production of reactive oxygen species (ROS) production 
(Shukkur et al., 2006, Conti et al., 2007, Valenti et al., 2010, Valenti et al., 2011, Brault et al., 
2015, Guedj et al., 2016). Ts1Cje mice were shown to have deficit in mitochondrial 
membrane potential and ATP production (Shukkur et al., 2006), while muscles from Ts3Yah 
mice were found to have decreased mitochondrial content and a slight increase in 
mitochondrial membrane permeability (Brault et al., 2015) and Ts65Dn hippocampal 
neuronal progenitor cells (NPCs) were found to be impaired in mitochondrial ATP synthesis 
and biogenesis (Valenti et al., 2016, Valenti et al., 2017). Those defects have been linked to 
alteration of the PGC1α/Sirt1/AMPK axis (Piccoli et al., 2013, Valenti et al., 2016), of the 
cAMP/PKA pathway and of proteins involved in mitochondrial fusion (Izzo et al., 2017, 
Valenti et al., 2017). Hsa21 genes having a role in energy and ROS metabolism are 
numerous: the MRPL39 and MRPS6 genes coding for mitochondrial ribosomal proteins, 
ATP5J and ATP5O encoding subunits of the mitochondrial ATP synthase, NDUFV3 encoding a 
subunit of the NADH-ubiquinone oxidoreductase complex of the respiratory chain or GABPA 
encoding a subunit of the nuclear respiratory transcription factor involved in activation of 
cytochrome oxidase expression and nuclear control of mitochondrial function. Moreover, 
DSCR1 coding for the inhibitor of calcineurin RCAN1 was found to alter mitochondrial fission 
in transgenic mice overexpressing it (Wong et al., 2015).  
 
IV. Future and perspectives 
The modelling of DS in animals has changed the field of DS research. From the early stages 
where a few candidate genes were overexpressed using additive transgenesis, to the 
chromosomal engineering and the transchromosomic strategies, animal models have evolved 
and boosted research to better understand the pathophysiology of the disease and stimulate 
therapeutic innovation with many preclinical treatments undergoing pre-clinial/clinical trials 
for human. As we have shown here, the models have progressed with a better knowledge on 
genome sequence and organisation in Human and animal models. Both have been key to 
make new animal models for DS moving from early phase to what now we can call V3.0 
models.  
DS models, especially in mouse, have been key to achieve progress in the understanding of 
the DS brain phenotypes. Nevertheless, we have focused on the gene content but have not 
so far considered higher genomic organisation, like the TADs that are quite well conserved as 
mentioned above. The development of the genetic toolbox allowing the precise modification 
of the genome with the additive transgenesis to the up-to-date CRISPR/CAS9 technology to 
engineer chromosome allows us now to make models in mouse and rat with better 
efficiency. The use of these techniques may be translated to other species in the future 
depending on the scientific question asked or the hypothesis to test.  Indeed, even if rodents 
are the most commonly used animal models, we should not forget that anatomical, 
morphological, and physiological differences will always limit the conclusions obtained from 
the results obtained in animal species. For example, the complexity of the human brain 
results from other steps of development with massive expansion of the cortical and 
cerebellar cortex. Such phenomena’s are not present in mouse and rat models but may be 
mimicked somehow in ferret or in Non-human primate, such as marmoset. 
The question now is how can we get better models to go further? Undeniably we should 
work with the whole set of genes homologous to Hsa21, either bringing together all the 
trisomies/duplication of regions homologous to Hsa21 in mouse and rats or use 
transchromosomic mice. This is supported by recent data showing an epistatic interaction 
between Dyrk1a and Cbs, located respectively on the Mmu16 and the Mmu17 homologous 
regions (Marechal et al., 2019b). Thus, it is really a challenge to get together DS models for 
the 3 chromosomal regions. An alternative is to get new transchromosomic model. 
Nevertheless, having human genes in a mouse context with human proteins and non-coding 
elements that are not tailored to work with the mouse components may induce new 
consequences that are not relevant to DS in people. The rat models may represent an 
alternative to the mouse with only two main regions to put together (Birling et al., 2017b); 
although this may be challenging because of elevation in still-birth in this model. 
Nevertheless, some additional data on their behavior profile are needed before going into 
this path. 
In the current models, the dimension of the genotypic space of DS features is not fully 
explored. First, we are missing genetic diversity in the mouse models to mimic the variability 
found in the penetrance and expressivity of features in individuals with DS. Incorporating the 
genetic diversity represent a major challenge as currently even with up to date initiative 
such as the Collaborative cross(Iraqi et al., 2012, Churchill et al., 2004), it represents a major 
challenge to cross all this DS genetic models in various lines. An alternative is to consider 
studying the phenotype outcomes in an outbred genetic background such as in the rat DS 
models (Birling et al., 2017b). Then, most of the current studies are done on one model for 
DS, the Ts65Dn mouse model, that is trisomic for a small subset of genes homologous to 
Hsa21, leaving aside some key genetic interactions between Hsa21 genes (Marechal et al., 
2019b). Finally, more specific to DS, some phenotype will never be recapitulated in the 
mouse brain. For example, the amyloid plaques deposition found in the Alzheimer’s disease 
(AD) brain in people with DS is not present in the brain of DS mouse models. This is due to 
the change in 3 amino-acid residues found in the sequence of the amyloid beta peptide 
derived from the mouse gene compared to the human. Thus, new humanized models at 
least for the App gene should be generated with a humanized App to better mimic the AD in 
DS.   
One way or another, the discovery of target genes from the Hsa21 homologous region will 
benefit from the direct use of the CRISPR/Cas9 technologies and the quick expansion of gene 
knock-out resource, done by the IMPC (www.mousephenotype.org). Thus, having access to a 
complete repertoire of mutants for genes homologous to Hsa21 represents a challenging 
goal that we should aim to complete linking with the IMPC. Nonetheless what have been 
achieved so far to mimic DS trisomy is tandem duplication, except for the Ts65Dn mouse 
model that is carrying a small segregating chromosome with the Mmu16 homologous region 
together with a small centromeric part of the Mmu17 containing non-homologous Hsa21 
genes. Thus, we should either refine the Ts65Dn model by removing the non-homologous 
region to Hsa21 or generate a new model with a segregating chromosome containing all the 
main regions homologous to Hsa21. This will also bring together the same context and 
organization, but the tools needed to achieve this goal are still to be either improved or 
described. 
Overall, the transposition of brain cognitive phenotype between human and animal models 
is still a challenge. Even though we can assess certain implicit or explicit memory functions in 
animal models, a standardization of methods may reduce the variability observed between 
datasets and increase the reproducibility of the results. The rat represents a new opportunity 
to investigate cognitive deficit in DS and to test preclinical drugs but we may consider other 
species in the future even more closely related to human.  
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VII. Tables  
 
 
  
Human Gorilla Chimpanzee Orangutan Mouse Rat Zebrafish Drosophila C.elegans 
Nb Human Genes Chr21 815         
Nb genes without 
homolog 
 569 554 583 607 602 661 717 732 
Nb homologs found  246 261 232 208 213 154 98 83 
Nb 
homologs  
per 
biotype 
category 
Protein 
coding 
232 200 207 193 192 193 143 97 83 
sncRNA 75 46 54 39 16 20 11 1 - 
lncRNA 305 - - - - - - - - 
Pseudogenes 188 - - - - - - - - 
TEC 15 - - - - - - - - 
Nb genes 
without 
homolog 
per 
biotype 
category 
Protein 
coding 
 32 25 39 40 39 89 135 149 
sncRNA  29 21 36 59 55 64 74 305 
lncRNA  305 305 305 305 305 305 305 188 
Pseudogenes  188 188 188 188 188 188 188 75 
TEC  15 15 15 15 15 15 15 15 
 
 
Table 1: Homologs to Hsa21 found in other species. Identifying the different number per 
biotype category and biotype. The data were denerated querying the ENSEMBL database 
using biomaRt on the 270219. The used assembly’s database versions are GRCh38.p12.v95, 
GRCm38.p6.v95, Rnor_6.0.v95, BDGP6.v95, Pan_tro 3.0.v95,  gorGor4.v95, PPYG2.v95, 
GRCz11.v95, WBcel235.v95. The number of genes per chromosome and per biotype 
category across species is indicated. 
 
Phenotypes Nb of 
genes 
Nb of 
Phenotypes 
List of genes 
behaviour/ neurological/ nervous 
system 
22 61 App, Atp5o, Bach1, Cbr3, Col18a1, Col6a2, Cstb, Dnajc28, 
Dop1b, Mx2, Pknox1, Synj1, Tiam1, Tmem50b,Trappc10, Kcne2, 
Hunk, Mx2, Rcan1 
Pre-natal or early mortality 16 46 Agpat3, Aire, App, Atp5o, Bach1, Erg, Gabpa, Gart, Hlcs, Lss, 
Morc3, Pdxk, Pfkl, Psmg1, Synj1, Wrb 
homeostasis/metabolism 19 49 4932438H23Rik, Agpat3, App, Bach1, Col18a1, Dnajc28, 
Dop1b, Fam207a, Hsf2bp, Il10rb, Kcne2, Lrrc3, Pknox1, S100b, 
Setd4, Spatc1l, Tff1, Hsf2bp, Slc37a1 
growth/ size/ body region 13 35 Chodl, Gart, Hsf2bp, Kcne2, Mx1, Ripk4, Sik1, Tff1, Tmprss15, 
Trappc10, Gabpa, Erg, Wrb 
hematopoietic system 9 23 Hsf2bp, Kcne2, Pknox1, Rbm11, Ripply3, S100b, Synj1, Tff1, 
Trappc10 
immune system 8 19 1810043G02Rik, Brwd1, Ifnar1, Lrrc3, Lss, Pknox1, Synj1, 
Tmprss15, Hsf2bp 
skeleton 8 15 Cbr3, Chodl, Dop1b, Sik1, Trappc10, Cstb, Setd4, Trappc10 
vision/ eye 6 15 Aire, Col18a1, Gabpa, Lss, Synj1, Ubash3a 
cardiovascular system 5 9 Hunk, Sik1, Slc37a1, Col18a1, Lss 
adipose tissue 3 5 Rcan1, Sik1,Trappc10 
integument 2 3 Brwd1, Dop1b 
reproductive system 3 4 Brwd1, Dnmt3l, Hsf2bp 
craniofacial  1 1 Gabpa 
Hearing system 1 1 Gabpa 
 
Table 2. Hsa21 homologs with known phenotypes in the mouse.  
 
 
VIII. Figure legends  
Figure 1. Comparison of the conserved Hsa21 homologous genes in different species. The 
respective organisation is preserved, and the localisation of protein-coding genes is indicated 
in blue square, pseudogenes in green, long non-coding genes in purple, short non-coding in 
red and genes to be experimentally conserved in orange. Landmarks for LIPI, ZBTB21-
UMODL1, RPR1B-PDXK and PRMT2 are shown respectively in red, black, grey and black. 
Figure 2. Human chromosome 21 syntenic regions in relative closer evolutionary species. 
The Hsa21 first and last genomic elements are found at 5.011 and 46.69 MBs (in blue). The 
syntenic regions containing orthologs with a one to one orthology relationship between the 
human gene and the animal species were used to build this representation. The orthologs 
genes in the chromosomes of 5 mammals are coloured differently depending on the 
chromosome they are found (yellow, dark blue, green and red) in the other species. 
Between brackets the length in MBs of the syntenic region conserved block relative to both 
the conserved human region length in blue and the length of the syntenic region in the 
animal species in black.  
Figure 3. The DYRK1A region is highly conserved in term of organisation and protein-
encoded sequence. A) Evolution tree of the chromosome 21 genes surrounding DYRK1A 
(arrow). The gene tree was build using Genomicus v95.01 Phyloview and is centred around 
DYRK1A. Every row represents a species and every gene is depicted in a specific colour. The 
homologs genes appear in the same colour on each species. Shaded genes correspond to genes 
that are not orthologous to any genes from human. B) Functional and sequence similarity wise 
DYRK1A gene tree taken from phylomeDB. 
Figure 4. TADs located in human chromosome 21 syntenic landscape in the mouse 
genome. Figures modified from the Yue lab Hi-C browser. http://promoter.bx.psu.edu/hi-c/). 
Genes in blue are on the reverse strand instead in black are on the forward strand. TADs are 
represented by the cream/grey bar. The human data displayed corresponds to the cortex Hi-
C map from the assembly version Hg19 with a resolution of 40 Kbs (Schmitt et al., 2016). The 
Mouse data, displayed corresponds to the neuronal cortex Hi-C map with a resolution of 25 
Kbs from the assembly version mm10 (Bonev et al., 2017). A) TADs landscape in the Hsa21 
syntenic mouse chr16. B) TADs landscape in the Hsa21 syntenic mouse chr17 and chr10. 
Figure 5: Models for DS in mouse and rat. Updated from (Herault et al., 2017). The Hsa21 
sequence is shown in blue with the corresponding rat (up) and mouse (down) homologous 
region respectively in Rno11 and 20, or Mmu16, 17 and 10. The relative position of the 
model is given with the official name and the size of the recombined interval.  
 
